Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

This study uses advanced genetic testing and functional drug screening on a patient's own cancer cells to identify the most effective treatment for patients with aggressive blood cancers that have stopped responding to standard therapies. The goal is to personalize treatment when standard options have been exhausted. **You may be eligible if:** - You have an aggressive blood cancer (such as leukemia or lymphoma) - You have already received at least two prior lines of treatment (or one treatment if no standard options remain) - Your last treatment response lasted less than 6 months - You are in good enough health (ECOG performance status 0-1) to receive further treatment - Tumor cell samples can be collected from you **You may NOT be eligible if:** - You are currently enrolled in another experimental clinical trial - You are pregnant - You have classical or nodular lymphocyte-predominant Hodgkin's lymphoma - You have been diagnosed with another cancer in the past year (with some exceptions for minor skin cancers) Talk to your doctor to see if this trial is right for you.